Clinical Trial Update: Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating hypofractionated accelerated pelvic nodal radiotherapy (GCC 2048) for prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Status: RECRUITING